Group 1 - Rapport Therapeutics, Inc. (NASDAQ:RAPP) is considered one of the best fast money stocks to buy, with JMP Securities reaffirming a 'Market Outperform' rating and a price target of $77, indicating a potential increase of approximately 174% [1] - The company has outperformed the market by 45% year-to-date, with a significant market of 1.8 million patients in the U.S., 40% of whom are treatment-resistant [2] - The leadership expressed enthusiasm about RAP-219 during a presentation, viewing it as a multibillion-dollar market opportunity, supported by its novel mechanism of action and best-in-class efficacy [3] Group 2 - Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing therapies for central nervous system disorders, and was incorporated in 2022 [4]
JMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study Success